These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31433056)
1. Resistance in patients failing integrase strand transfer inhibitors: a call to replace raltegravir with dolutegravir in third-line treatment in South Africa. Steegen K; van Zyl G; Letsoalo E; Claassen M; Hans L; Carmona S Open Forum Infect Dis; 2019 Aug; 6(10):. PubMed ID: 31433056 [TBL] [Abstract][Full Text] [Related]
2. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study. Santos JR; Casadellà M; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; García-Vallecillos C; Vivancos MJ; Imaz A; Iribarren JA; Hernández-Quero J; Villar-García J; Barrufet P; Paredes R; Front Cell Infect Microbiol; 2023; 13():1187999. PubMed ID: 37434782 [TBL] [Abstract][Full Text] [Related]
5. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance. Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878 [TBL] [Abstract][Full Text] [Related]
6. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A; Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199 [TBL] [Abstract][Full Text] [Related]
7. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1. Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975 [TBL] [Abstract][Full Text] [Related]
8. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis. Ngoufack Jagni Semengue E; Santoro MM; Ndze VN; Ka'e AC; Yagai B; Nka AD; Dambaya B; Takou D; Teto G; Fabeni L; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J PLOS Glob Public Health; 2022; 2(10):e0000826. PubMed ID: 36962573 [TBL] [Abstract][Full Text] [Related]
9. Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Dow DE; Bartlett JA Infect Dis Ther; 2014 Dec; 3(2):83-102. PubMed ID: 25134686 [TBL] [Abstract][Full Text] [Related]
10. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A; Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050 [TBL] [Abstract][Full Text] [Related]
11. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials. You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149 [TBL] [Abstract][Full Text] [Related]
13. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291 [TBL] [Abstract][Full Text] [Related]
14. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578 [TBL] [Abstract][Full Text] [Related]
15. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG; Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 resistance to dolutegravir: update and new insights. Wainberg MA; Han YS J Virus Erad; 2015 Jan; 1(1):13-6. PubMed ID: 27482391 [TBL] [Abstract][Full Text] [Related]
17. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. Yang LL; Li Q; Zhou LB; Chen SQ Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480 [TBL] [Abstract][Full Text] [Related]
19. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens. Gil H; Delgado E; Benito S; Moreno-Lorenzo M; Thomson MM; Front Microbiol; 2022; 13():1051096. PubMed ID: 36578581 [TBL] [Abstract][Full Text] [Related]
20. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG; J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]